A study has revealed that complete suppression of hepatitis B virus or HBV has increased from 91.9% at tenofovir alafenamide or TAF switch following use of entecavir for an average of 6 months to 97.2% at 96 weeks later.
 |
| Photo: Hepatitis B Virus Affecting Liver | InStyleHealth |
Researchers enrolled entecavir-treated chronic
hepatitis B patients who switched to TAF in routine practice at 15 centers in
the US, Korea, Japan, and Taiwan. A complete viral suppression rate was the primary
endpoint.
There was a total of 425 patients with an average age
of 60.7 years old, were analyzed, of whom 60% were men, 90.8% were Asians,
20.7% had diabetes, 27% were hypertensive, 14.8% had cirrhosis, and 8.3% had
hepatocellular carcinoma. Average entecavir use prior to TAF switch was 6.16
years, while the mean baseline estimated glomerular filtration rate or eGFR was
89 mL/min/1.73 m2.
Complete viral suppression rate has risen from 91.90% at
TAF switch to 95.57% and 97.21% at 48 and 96 weeks thereafter.
Throughout the 96 weeks following the TAF switch,
average HBV DNA reduced but not alanine aminotransferase or CKD (Chronic Kidney
Disease) stage. Between the switch and 96-week follow-up, 11% of CKD stage 1 patients
worsened to stage 2 and 8% of stage 2 patients to stages 3-5; however, 18% of
CKD stage 2 patients migrated to stage 1 and 19% from stages 3-5 to stage 2.
Using multivariable generalized estimate equation analysis
has showed the correlation of baseline eGFR, age, and CKD stage 2 and 3-5 with
lower follow-up eGFR, adjusted for age, gender, diabetes, hypertension, and
cirrhosis.
Source: Am J Gastroenterol 2021;116:1264-1273